» Articles » PMID: 22271340

Interleukin-1 Receptor Antagonist: a New Therapy for Type 2 Diabetes Mellitus

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2012 Jan 25
PMID 22271340
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Various complex mechanisms and their multifactorial pathways decisively provoke low-grade local and systemic inflammation in β-cells of pancreatic islets and peripheral tissues to induce β-cells' dysfunction and apoptosis, insulin resistance, and ultimately, overt type 2 diabetes mellitus (T2DM). Conventional antidiabetic agents are being less popular, as they have some potential adverse effects. Currently, many anti-inflammatory therapeutic modalities are being investigated to abate the infuriating effects of inducers of T2DM and among them, interleukin-1 receptor antagonist (IL-1Ra) is the only one that has been approved by US Food and Drug Administration. We have compared IL-1Ra with other anti-inflammatory agents and conventional antidiabetic agents. Although, IL-1Ra has broad-spectrum anti-inflammatory activities, it also has some limitations due to its short half-life. To overcome the problem of short half-life of IL-1Ra, recently, we fused IL-1Ra in recombinant human serum albumin and expressed it in Pichia pastoris. Its bioactivity was also checked by IL-1-induced A375.S2 apoptotic cells. Furthermore, we have also formulated IL-1Ra with Pluronic F-127-based thermosensitive gel and investigated its in vitro characteristics to prolong its therapeutic effects. Further studies are required to investigate its therapeutic effects against diabetes and diabetes-associated complications.

Citing Articles

Curcumin-loaded bioadhesive silk fibroin microsphere improves islet transplantation by mitigating oxidative stress and inhibiting apoptosis.

Yang C, Yu R, Zhang Y, Wang Q, Huang D, Cheng Y Mater Today Bio. 2025; 31:101507.

PMID: 39925714 PMC: 11804778. DOI: 10.1016/j.mtbio.2025.101507.


From sugar binders to diabetes fighters: the lectin saga of antihyperglycemic activity through systematic review and meta-analysis.

Simha N A, Patil S, M K J, N C, Shing Wong L, Kijsomporn J Front Pharmacol. 2024; 15:1382876.

PMID: 39323638 PMC: 11422237. DOI: 10.3389/fphar.2024.1382876.


Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies.

Elkanawati R, Sumiwi S, Levita J Drug Des Devel Ther. 2024; 18:3337-3360.

PMID: 39100221 PMC: 11298177. DOI: 10.2147/DDDT.S468147.


Therapeutic proteins: developments, progress, challenges, and future perspectives.

Kumar V, Barwal A, Sharma N, Mir D, Kumar P, Kumar V 3 Biotech. 2024; 14(4):112.

PMID: 38510462 PMC: 10948735. DOI: 10.1007/s13205-024-03958-z.


Association Between Interleukin-6 Gene Polymorphism and Severity of Coronary Artery Disease in Patients with Diabetes.

Yao H, Pang Y, Chen Y, Si N, Wu C, Wang Z Diabetes Metab Syndr Obes. 2023; 16:3599-3608.

PMID: 37964941 PMC: 10642489. DOI: 10.2147/DMSO.S427873.